weight loss surgery vs glp-1 agonists bariatric comparison Metabolic and versus glucagon-like peptide-1 receptor agonist therapy: A of cardiovascular outcomes in patients with obesity Bariatric Surgery Yields 5x More – The data speaks for itself.

The FDA has warned about compounded GLP-1 drugs due to dosing errors, questionable ingredients, and reports of adverse events

A medical provider can help determine the most appropriate strategy

Addressing sleep hygiene is a clinical priority during any tapering plan

GLP-1s have caught attention in Alzheimers research because they modulate brain insulin signaling and systemic metabolism two factors deeply intertwined with such underlying issues

Orforglipron, made by the same company that produces the GLP-1 medications Zepbound and Mounjaro (tirzepatide), is an oral medication undergoing FDA clinical tests for use in weight loss

Keep scrolling for more health stories